scFv(HER2)-OX40-CD3zeta CAR-T Lentivirus

scFv(HER2)-OX40-CD3ζ CAR-T Lentivirus is a gene-delivery reagent designed to generate T cells that recognize human epidermal growth factor receptor 2 (HER2/ERBB2). The encoded second-generation chimeric antigen receptor combines an extracellular anti-HER2 single-chain variable fragment (scFv) with membrane-anchoring elements, the intracellular costimulatory domain of OX40 (CD134), and the CD3ζ activation domain. The scFv provides antibody-like recognition of cell-surface HER2 without requiring major histocompatibility complex presentation. After antigen engagement, CD3ζ initiates the primary activation signal, while OX40 supplies additional signaling associated with T-cell survival, proliferation, cytokine production, and resistance to activation-induced cell death. Lentiviral delivery supports efficient gene transfer and stable CAR expression in transduced T cells, providing a consistent platform for studying HER2-directed immune responses and the contribution of OX40 costimulation.

This product is intended for research on HER2-targeted cellular immunotherapy and the functional characterization of OX40-based CAR designs. Experimental CAR-T cells generated with the lentivirus can be assessed for receptor expression, antigen-dependent activation, target-cell killing, cytokine secretion, expansion, survival, and changes in memory or exhaustion phenotypes. Researchers may compare HER2-high, HER2-low, and HER2-negative target cells to examine antigen-density thresholds, specificity, and potential on-target effects across different expression levels. The resulting cells are suitable for appropriately designed studies involving HER2-expressing breast, gastric, ovarian, lung, and other solid-tumor models. This construct can also serve as a reference when comparing OX40 with first-generation CARs or receptors containing CD28 or 4-1BB costimulatory domains. Further applications include investigating repeated antigen exposure, tumor-cell resistance, immune escape, and CAR-T-cell performance under immunosuppressive conditions.